<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037487</url>
  </required_header>
  <id_info>
    <org_study_id>21-001137</org_study_id>
    <nct_id>NCT05037487</nct_id>
  </id_info>
  <brief_title>Evaluation of Smoked THC and CBD in Men and Women</brief_title>
  <acronym>S-TACOFS</acronym>
  <official_title>Evaluation of Smoked THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of&#xD;
      inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol&#xD;
      (CBD) and to evaluate detection of recently smoked THC in oral fluid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double-blind placebo controlled, within-subject study study will assess testing devices&#xD;
      that can measure biochemical markers in oral fluid and neurocognitive-performance markers of&#xD;
      recent cannabis use. Other pharmacodynamic effects of inhaled cannabis with CBD and THC will&#xD;
      be determined and the pharmacokinetics of THC, CBD, and respective metabolites will be&#xD;
      assessed in whole blood.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective drug effect ratings of impairment and abuse liability</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak subjective ratings of drug effects associated with abuse liability and impairment as measured using visual analogue scales (VAS; 1-100mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of THC, CBD and metabolites</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak blood levels of THC, CBD, 11-OH-THC, and THCCOOH after exposure (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral task performance as assessed by the DRUID App Score</measure>
    <time_frame>6 hour</time_frame>
    <description>Trough composite scores on the DRUID App</description>
  </primary_outcome>
  <primary_outcome>
    <measure>THC concentrations in oral fluid</measure>
    <time_frame>6 hour</time_frame>
    <description>Peak levels of THC in oral fluid after exposure</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Drug Abuse</condition>
  <condition>Intoxication by Drug</condition>
  <condition>Impairment</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Smoked placebo cannabis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg CBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked cannabis with CBD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg CBD + 20 mg THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked cannabis with CBD and THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked cannabis with THC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cannabis</intervention_name>
    <description>Smoked placebo cannabis</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg CBD Cannabis</intervention_name>
    <description>Smoked cannabis with CBD</description>
    <arm_group_label>20 mg CBD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg CBD + 20 mg THC Cannabis</intervention_name>
    <description>Smoked cannabis with CBD and THC</description>
    <arm_group_label>20 mg CBD + 20 mg THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg THC Cannabis</intervention_name>
    <description>Smoked cannabis with THC</description>
    <arm_group_label>20 mg THC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant and non-lactating females aged 21-55 years&#xD;
&#xD;
          -  Report weekly-monthly use of cannabis (â‰¤1 day per week) over the past month prior to&#xD;
             screening,&#xD;
&#xD;
          -  Not currently seeking treatment for their cannabis use&#xD;
&#xD;
          -  Have a Body Mass Index from 18.5 - 34kg/m2.&#xD;
&#xD;
          -  Able to perform all study procedures&#xD;
&#xD;
          -  Must be using a contraceptive (hormonal or barrier methods)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any&#xD;
             substance use disorder other than nicotine, caffeine&#xD;
&#xD;
          -  Any other Axis I disorder&#xD;
&#xD;
          -  Report using other illicit drugs in the prior 4 weeks, other than cannabis.&#xD;
&#xD;
          -  Current use of any medications that may affect study outcomes&#xD;
&#xD;
          -  If medical history, physical and psychiatric examination, or laboratory tests&#xD;
             performed during the screening process are not within the normal range and / or reveal&#xD;
             any significant illness (e.g., hypertension) as judged by the study physician and to&#xD;
             put the participant at greater risk of experiencing adverse events due to completion&#xD;
             of study procedures.&#xD;
&#xD;
          -  Pregnancy is exclusionary due to the possible effects of the study medication on fetal&#xD;
             development.&#xD;
&#xD;
          -  History of an allergic reaction or adverse reaction to cannabis is exclusionary.&#xD;
&#xD;
          -  History of respiratory illness or current respiratory illness&#xD;
&#xD;
          -  Currently enrolled in another research protocol&#xD;
&#xD;
          -  Not using a contraceptive method (hormonal or barrier methods)&#xD;
&#xD;
          -  The evaluating physician reviews all medical assessments along with medical history.&#xD;
             Any disorders that might make cannabis administration hazardous are exclusionary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziva Cooper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziva Cooper, PhD</last_name>
    <phone>310-206-9942</phone>
    <email>zcooper@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ziva Cooper, PhD</last_name>
      <phone>310-206-9942</phone>
      <email>zcooper@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vincent Acebo, PhD</last_name>
      <phone>310-983-3417</phone>
      <email>vacebo@mednet.ucla.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Ziva D. Cooper, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cannabis</keyword>
  <keyword>THC</keyword>
  <keyword>CBD</keyword>
  <keyword>Intoxication</keyword>
  <keyword>Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

